Jeffrey Ayer

Since joining Golden Flag, Jeff's representative matters have included:

• HGGC in its $240 million joint investment in Fullscript with Snapdragon Capital Partners.
• Amer Sports, along with its investor consortium, in its $420 million sale of Amer’s Precor division to Peloton.
• Bristol Myers Squibb in its $13.1 billion acquisition of MyoKardia.
• The Special Committee of the Board of Directors of Taubman Centers, Inc. in Taubman’s $9.8 billion merger and joint venture with Simon Property Group.
• GlaxoSmithKline in its acquisition of Pfizer’s consumer healthcare business.
• Fortive Corporation in Industrial Scientific’s $570 million acquisition of Intelex Technologies.
• WellCare Health Plans in its $17.3 billion acquisition by Centene Corporation.
• Boeing in its $4.2 billion acquisition of KLX Inc., a provider of aviation parts and services.
• Boeing in its acquisition of Millennium Space Systems, a developer and manufacturer of military satellites.
• Fortive Corporation for its $770 million acquisition of Landauer, a provider of radiation safety and outsourced medical physics.
• Secured U.S. antitrust clearance for the merger of SSI and Research Now, two leading leading providers of online panel data.
• WellCare Health Plans to secure antitrust clearance for its $2.5 billion acquisition of Meridian Health Plans.

Prior to joining Golden Flag, Jeff’s representative matters included:

• Regal Entertainment Group in state and federal antitrust litigation brought by competing theatre owners.

• U.S. antitrust clearance for the combination of the two largest Bible publishers in the United States.

• Qwest in its merger with CenturyLink.

• Mayne Pharma Ltd. in its acquisition by Hospira Inc.

• Regal Entertainment in several transactions in the movie theater industry, including Regal's merger with United Artists Theatre Company, and its acquisitions of Edwards Theatres, Signature Theatres, Eastern Federal Theatres, and Consolidated Theatres.

• As part of the district court and appellate litigation teams in United States v. LSL Biotechnologies, Inc., Jeff helped convince the district court to dismiss, and the appellate court to affirm the dismissal of, the government's case on the grounds that U.S. courts lacked jurisdiction under the Foreign Trade Antitrust Improvements Act.

• Represented a client before the Antitrust Division in a market allocation investigation that had been handled by another firm for three years, helping to persuade the Antitrust Division in less than six months to close its investigation with no enforcement action.